Nanobiotix S.A (NANO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Nanobiotix S.A (NANO) has a cash flow conversion efficiency ratio of 0.253x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-17.41 Million ≈ $-20.36 Million USD) by net assets (€-68.95 Million ≈ $-80.61 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Nanobiotix S.A - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Nanobiotix S.A's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read NANO total liabilities for a breakdown of total debt and financial obligations.
Nanobiotix S.A Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Nanobiotix S.A ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Financial Street Holdings Co Ltd
SHE:000402
|
0.015x |
|
Abaxx Technologies Inc
NEO:ABXX
|
-0.411x |
|
Msscorps Co Ltd
TW:6830
|
0.069x |
|
Techwing Inc
KQ:089030
|
0.014x |
|
Elite Advanced Laser Corp
TW:3450
|
0.078x |
|
HNA Technology Co Ltd A
SHG:600751
|
0.011x |
|
Allegiant Travel Company
NASDAQ:ALGT
|
0.107x |
|
Orchid Island Capital Inc.
NYSE:ORC
|
0.035x |
Annual Cash Flow Conversion Efficiency for Nanobiotix S.A (2011–2024)
The table below shows the annual cash flow conversion efficiency of Nanobiotix S.A from 2011 to 2024. For the full company profile with market capitalisation and key ratios, see NANO company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €-65.70 Million ≈ $-76.81 Million |
€-19.55 Million ≈ $-22.86 Million |
0.298x | -95.60% |
| 2023-12-31 | €-1.84 Million ≈ $-2.15 Million |
€-12.48 Million ≈ $-14.59 Million |
6.769x | +393.43% |
| 2022-12-31 | €-27.05 Million ≈ $-31.62 Million |
€-37.10 Million ≈ $-43.38 Million |
1.372x | +218.11% |
| 2021-12-31 | €26.69 Million ≈ $31.21 Million |
€-31.00 Million ≈ $-36.25 Million |
-1.162x | -189.43% |
| 2020-12-31 | €70.36 Million ≈ $82.26 Million |
€-28.24 Million ≈ $-33.01 Million |
-0.401x | -101.97% |
| 2019-12-31 | €-2.04 Million ≈ $-2.38 Million |
€-41.52 Million ≈ $-48.54 Million |
20.362x | +1216.11% |
| 2018-12-31 | €14.24 Million ≈ $16.65 Million |
€-25.98 Million ≈ $-30.38 Million |
-1.824x | -282.51% |
| 2017-12-31 | €43.92 Million ≈ $51.35 Million |
€-20.95 Million ≈ $-24.49 Million |
-0.477x | +54.61% |
| 2016-12-31 | €17.40 Million ≈ $20.34 Million |
€-18.28 Million ≈ $-21.38 Million |
-1.051x | +2.47% |
| 2015-12-31 | €15.61 Million ≈ $18.25 Million |
€-16.82 Million ≈ $-19.66 Million |
-1.077x | -281.37% |
| 2014-12-31 | €30.32 Million ≈ $35.44 Million |
€-8.56 Million ≈ $-10.01 Million |
-0.283x | +86.84% |
| 2013-12-31 | €3.18 Million ≈ $3.72 Million |
€-6.83 Million ≈ $-7.99 Million |
-2.147x | -506.57% |
| 2012-12-31 | €10.70 Million ≈ $12.51 Million |
€-3.79 Million ≈ $-4.43 Million |
-0.354x | +93.28% |
| 2011-12-31 | €925.53K ≈ $1.08 Million |
€-4.87 Million ≈ $-5.70 Million |
-5.265x | -- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more